Stay updated on TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial

Sign up to get notified when there's something new on the TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    Added Melanoma as a related topic and added MedlinePlus Genetics; updated the revision tag from v3.4.3 to v3.5.0.
    Difference
    0.2%
    Check dated 2026-03-19T05:24:49.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    Added Revision: v3.4.3; deleted Melanoma and related topics (MedlinePlus Genetics); Revision: v3.4.2.
    Difference
    0.2%
    Check dated 2026-03-12T02:27:38.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    - Melanoma added as a related topic and a MedlinePlus Genetics entry added to related topics.
    Difference
    0.1%
    Check dated 2026-03-04T23:54:50.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    Melanoma and the related topic MedlinePlus Genetics were removed from the page.
    Difference
    0.1%
    Check dated 2026-02-25T20:27:25.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    Added Melanoma as a related topic and linked MedlinePlus Genetics as a related topics resource on the page. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-18T16:46:54.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2. Removed the older Revision: v3.4.1 and the government funding operating-status notice.
    Difference
    0.4%
    Check dated 2026-02-11T14:08:45.000Z thumbnail image

Stay in the know with updates to TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial page.